ContraVir Pharmaceuticals (NASDAQ:CTRV) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
Separately, ValuEngine upgraded ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
ContraVir Pharmaceuticals (NASDAQ:CTRV) traded up $0.04 during trading hours on Tuesday, hitting $0.29. The company had a trading volume of 8,392,400 shares, compared to its average volume of 985,309. ContraVir Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $1.96. The firm has a market cap of $19.71, a price-to-earnings ratio of -0.59 and a beta of 1.92.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.